Sunesis Pharmaceuticals Inc (SNSS): Cormorant Asset Management Reports New 5.14% Stake

Page 6 of 10

Page 6 of 10 – SEC Filing
CUSIP NO.
867328502
Item 1.
(a)
Name of Issuer
Sunesis Pharmaceuticals, Inc.
(b)
Address of Issuer’s Principal Executive Offices
395 Oyster Point Boulevard, Suite 400
South San Francisco, CA 94080
Item 2.
(a)
Name of Person Filing
Cormorant Global Healthcare Master Fund, LP
Cormorant Global Healthcare GP, LLC
Cormorant Asset Management, LLC
Bihua Chen
(b)
Address of Principal Business Office or, if none, Residence
200 Clarendon Street, 52nd Floor
Boston, MA 02116
(c)
Citizenship
Cormorant Global Healthcare Master Fund, LP – Cayman Islands
Cormorant Global Healthcare GP, LLC – Delaware
Cormorant Asset Management, LLC – Delaware
Bihua Chen – United States
(d)
Title of Class of Securities
Common Stock
(e)
CUSIP Number
867328502

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 6 of 10